The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II, open-label trial of orally administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or intolerant to hydroxyurea.
Ayalew Tefferi
No relevant relationships to disclose
Jorge E. Cortes
Research Funding - Sanofi
Andreas Hochhaus
Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Merck; Novartis; Pfizer
Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Sanofi
Jean-Jacques Kiladjian
Research Funding - Celgene; Novartis; Shire
Ruben A. Mesa
Research Funding - Sanofi
Animesh Dev Pardanani
No relevant relationships to disclose
Claudia Lebedinsky
Employment or Leadership Position - Sanofi
Frank Neumann
Employment or Leadership Position - Sanofi
Karl Hsu
Employment or Leadership Position - Sanofi
Alessandro M. Vannucchi
Consultant or Advisory Role - Italfarmaco; Novartis
Honoraria - Italfarmaco; Novartis